Virtual screening against metalloenzymes for inhibitors and substrates.

Molecular docking uses the three-dimensional structure of a receptor to screen databases of small molecules for potential ligands, often based on energetic complementarity. For many docking scoring functions, which calculate nonbonded interactions, metalloenzymes are challenging because of the partial covalent nature of metal-ligand interactions. To investigate how well molecular docking can identify potential ligands of metalloenzymes using a "standard" scoring function, we have docked the MDL Drug Data Report (MDDR), a functionally annotated database of 95,000 small molecules, against the X-ray crystal structures of five metalloenzymes. These enzymes included three zinc proteases, the nickel analogue of an iron enzyme, and a molybdenum metalloenzyme. The ability of the docking program to retrospectively enrich the annotated ligands as high-scoring hits for each enzyme and to calculate proper geometries was evaluated. In all five systems, the annotated ligands within the MDDR were enriched at least 20 times over random. To test the approach prospectively, a sixth target, the zinc beta-lactamase from Bacteroides fragilis, was screened against the fragment-like subset of the ZINC database. We purchased and tested 15 compounds from among the top 50 top-ranked ligands from docking, and found 5 inhibitors with apparent K(i) values less than 120 microM, the best of which was 2 microM. A more ambitious test still was predicting actual substrates for a seventh target, a Zn-dependent phosphotriesterase from Pseudomonas diminuta. Screening the Available Chemicals Directory (ACD) identified 25 thiophosphate esters as potential substrates within the top 100 ranked compounds. Eight of these, all previously uncharacterized for this enzyme, were acquired and tested, and all were confirmed experimentally as substrates. These results suggest that a simple, noncovalent scoring function may be used to identify inhibitors of at least some metalloenzymes.

[1]  K. Merz,et al.  A quantum mechanics-based scoring function: study of zinc ion-mediated ligand binding. , 2004, Journal of the American Chemical Society.

[2]  R. Bradshaw,et al.  Methionine aminopeptidases and angiogenesis. , 2002, Essays in biochemistry.

[3]  F. Raushel,et al.  Purification and properties of the phosphotriesterase from Pseudomonas diminuta. , 1989, The Journal of biological chemistry.

[4]  P. Fitzgerald,et al.  Unanticipated inhibition of the metallo-beta-lactamase from Bacteroides fragilis by 4-morpholineethanesulfonic acid (MES): a crystallographic study at 1.85-A resolution. , 1998, Biochemistry.

[5]  J. Koehn,et al.  N-Alkyl Urea Hydroxamic Acids as a New Class of Peptide Deformylase Inhibitors with Antibacterial Activity , 2002, Antimicrobial Agents and Chemotherapy.

[6]  G. Rosenberg,et al.  Tissue Inhibitor of Metalloproteinase-3 is Associated with Neuronal Death in Reperfusion Injury , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  Brian K Shoichet,et al.  Protein–protein docking with multiple residue conformations and residue substitutions , 2002, Protein science : a publication of the Protein Society.

[8]  G C Roberts,et al.  Thiomandelic acid, a broad spectrum inhibitor of zinc beta-lactamases: kinetic and spectroscopic studies. , 2001, The Journal of biological chemistry.

[9]  Magali Mathieu,et al.  The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents. , 2002, Journal of molecular biology.

[10]  Richard H. Henchman,et al.  From model complexes to metalloprotein inhibition: a synergistic approach to structure-based drug discovery. , 2003, Angewandte Chemie.

[11]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[12]  D. Vanderwall,et al.  Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-beta-lactamase. , 1998, Chemistry & biology.

[13]  B. Shoichet,et al.  Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. , 2003, Journal of medicinal chemistry.

[14]  S H Kaufmann,et al.  Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. , 2000, Journal of medicinal chemistry.

[15]  Christopher W Murray,et al.  Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.

[16]  P. Rajagopalan,et al.  Structural basis for the design of antibiotics targeting peptide deformylase. , 1999, Biochemistry.

[17]  F. Winkler,et al.  Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. , 2000, Journal of molecular biology.

[18]  F. Young Biochemistry , 1955, The Indian Medical Gazette.

[19]  Brian K. Shoichet,et al.  Molecular docking using shape descriptors , 1992 .

[20]  I. Kuntz,et al.  Automated docking with grid‐based energy evaluation , 1992 .

[21]  D. Payne,et al.  Inhibition of metallo-beta-lactamases by a series of mercaptoacetic acid thiol ester derivatives , 1997, Antimicrobial agents and chemotherapy.

[22]  S. Swaminathan,et al.  A novel mechanism for Clostridium botulinum neurotoxin inhibition. , 2002, Biochemistry.

[23]  Oonagh Dowling,et al.  Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome , 2001, Nature Genetics.

[24]  P. Calí,et al.  Isoxazole-3-hydroxamic acid derivatives as peptide deformylase inhibitors and potential antibacterial agents. , 2004, Bioorganic & medicinal chemistry letters.

[25]  A. Bendele,et al.  Induction of osteoarthritis in the rat by surgical tear of the meniscus: Inhibition of joint damage by a matrix metalloproteinase inhibitor. , 2002, Osteoarthritis and cartilage.

[26]  W. Haynes,et al.  Xanthine Oxidase Inhibition Reverses Endothelial Dysfunction in Heavy Smokers , 2003, Circulation.

[27]  J. Irwin,et al.  ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .

[28]  Ingo Muegge,et al.  Evaluation of docking/scoring approaches: A comparative study based on MMP3 inhibitors , 2000, J. Comput. Aided Mol. Des..

[29]  R. Ambler,et al.  The structure of beta-lactamases. , 1980, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[30]  G. Cornaglia,et al.  Appearance of IMP-1 metallo-beta-lactamase in Europe. , 1999, Lancet.

[31]  Martin J. Field,et al.  Parametrization of a force field for metals complexed to biomacromolecules: applications to Fe(II), Cu(II) and Pb(II) , 2002, J. Comput. Aided Mol. Des..

[32]  C. Perry,et al.  Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension. , 2003, Drugs & aging.

[33]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[34]  F. Raushel,et al.  High resolution X-ray structures of different metal-substituted forms of phosphotriesterase from Pseudomonas diminuta. , 2001, Biochemistry.

[35]  B. Shoichet,et al.  Flexible ligand docking using conformational ensembles , 1998, Protein science : a publication of the Protein Society.

[36]  P. Giral,et al.  Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives , 2004, Clinical chemistry and laboratory medicine.

[37]  D. Rice,et al.  Antibiotic Activity and Characterization of BB-3497, a Novel Peptide Deformylase Inhibitor , 2001, Antimicrobial Agents and Chemotherapy.

[38]  D. Christianson,et al.  Design of amino acid sulfonamides as transition-state analogue inhibitors of arginase. , 2003, Journal of the American Chemical Society.

[39]  D. Christianson,et al.  Design of Amino Acid Aldehydes as Transition-state Analogue Inhibitors of Arginase , 2003 .

[40]  V. E. Lewis,et al.  Structure-activity relationships in the hydrolysis of substrates by the phosphotriesterase from Pseudomonas diminuta. , 1989, Biochemistry.

[41]  A. Mai,et al.  3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. , 2004, Journal of medicinal chemistry.

[42]  Martin Stahl,et al.  Modifications of the scoring function in FlexX for virtual screening applications , 2000 .

[43]  Daniel A. Gschwend,et al.  Orientational sampling and rigid‐body minimization in molecular docking , 1993, Proteins.

[44]  Brian K Shoichet,et al.  Testing a flexible-receptor docking algorithm in a model binding site. , 2004, Journal of molecular biology.

[45]  Xin Hu,et al.  Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction. , 2003, Journal of molecular graphics & modelling.

[46]  Donald G. Truhlar,et al.  New Class IV Charge Model for Extracting Accurate Partial Charges from Wave Functions , 1998 .

[47]  Yuan-Ping Pang,et al.  Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. , 2000, Journal of medicinal chemistry.

[48]  Kenneth M. Merz,et al.  Force Field Design for Metalloproteins , 1991 .

[49]  S. Balaz,et al.  A practical approach to docking of zinc metalloproteinase inhibitors. , 2004, Journal of molecular graphics & modelling.

[50]  V S Patel,et al.  Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines. , 2001, Journal of medicinal chemistry.

[51]  F. Medeiros,et al.  Medical backgrounders: glaucoma. , 2002, Drugs of today.

[52]  M Karplus,et al.  Zinc binding in proteins and solution: A simple but accurate nonbonded representation , 1995, Proteins.

[53]  J. Madura,et al.  Docking of sulfonamides to carbonic anhydrase II and IV. , 2000, Journal of molecular graphics & modelling.

[54]  J. Starrett,et al.  Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis. , 2003, The Journal of rheumatology.

[55]  W. Figg,et al.  TNP-470: an angiogenesis inhibitor in clinical development for cancer , 2000, Expert opinion on investigational drugs.

[56]  B. Honig,et al.  Calculation of electrostatic potentials in an enzyme active site , 1987, Nature.

[57]  B. Matthews,et al.  A model binding site for testing scoring functions in molecular docking. , 2002, Journal of molecular biology.

[58]  T. Cierpicki,et al.  The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity. , 2003, Journal of medicinal chemistry.

[59]  W. Kabsch,et al.  Structure of Peptide Deformylase and Identification of the Substrate Binding Site* , 1998, The Journal of Biological Chemistry.

[60]  N. Woodford,et al.  Carbapenemases: a problem in waiting? , 2000, Current opinion in microbiology.

[61]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[62]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[63]  C. Enroth,et al.  Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[64]  H. Matter,et al.  Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship. , 2002, Bioorganic & medicinal chemistry.

[65]  M. Totrov,et al.  A novel class of inhibitors of peptide deformylase discovered through high-throughput screening and virtual ligand screening. , 2004, Journal of medicinal chemistry.

[66]  J J Baldwin,et al.  Positions of His‐64 and a bound water in human carbonic anhydrase II upon binding three structurally related inhibitors , 1994, Protein science : a publication of the Protein Society.